Search
Investors
Careers
Investors
Careers
Company
Our Story
Leadership & Advisors
Pillar News
Distribution Partners
Strategic Partnership
Technology
Products
Portfolio Overview
IVD Products
Solid Tumor Tissue
Liquid Biopsy
Heme
BRCA, HRD, Methylation
InheritRevealâ„¢ Disease
Pharma
Resources
Resource Overview
Webinars and Presentations
Publications
Posters
Contact
Company
Our Story
Leadership & Advisors
Pillar News
Distribution Partners
Strategic Partnership
Technology
Products
Portfolio Overview
IVD Products
Solid Tumor Tissue
Liquid Biopsy
Heme
BRCA, HRD, Methylation
InheritRevealâ„¢ Disease
Pharma
Resources
Resource Overview
Webinars and Presentations
Publications
Posters
Contact
Company
Our Story
Leadership & Advisors
Pillar News
Distribution Partners
Strategic Partnership
Technology
Products
Portfolio Overview
IVD Products
Solid Tumor Tissue
Liquid Biopsy
Heme
BRCA, HRD, Methylation
Inherited Disease
Pharma
Resources
Resource Overview
Webinars and Presentations
Publications
Posters
Contact
Careers
Investors
Company
Our Story
Leadership & Advisors
Pillar News
Distribution Partners
Strategic Partnership
Technology
Products
Portfolio Overview
IVD Products
Solid Tumor Tissue
Liquid Biopsy
Heme
BRCA, HRD, Methylation
Inherited Disease
Pharma
Resources
Resource Overview
Webinars and Presentations
Publications
Posters
Contact
Careers
Investors
Presentations
Laboratory Validation of Pillar’s onocoReveal Myeloid Panel on the Illumina MiSeq i100 to Deliver Rapid Front-Line NGS for Heme Malignancies
Event Name:
AMP 2025
TBC
Tags
Resource Topic
Heme
Year
2025